Managed Healthcare Executive September 7, 2021
Peter Wehrwein

For an assortment of reasons, the federal government hasn’t taken any action on regulating drug prices, so a handful of states have taken matters into their own hands.

For an assortment of reasons, the federal government hasn’t taken any action on regulating drug prices, so a handful of states have taken matters into their own hands. New York, Massachusetts, Maine, Maryland and New Hampshire have established entities with drug pricing powers. Harvard Medical School researchers published an informative overview of the state government efforts in the Milbank Quarterly in August.

As happens when healthcare policy devolves to the states, there’s a lot of variety in how the state-level drug pricing regulation is playing out. The Maine and New Hampshire drug...

Today's Sponsors

ZeOmega
Holon
Transcarent

Today's Sponsors

Crossover Health
Qure4u

Today's Sponsor

Institute for Healthcare Improvement

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending, States
Xilio, Ventyx IPOs raise $269M to fuel plans to compete with big pharma drugs
How are the European pharma and biotech sectors addressing strategic communications?
FDA Highlights Value and Challenges of Advanced Drug Manufacturing
Drug overdoses surged during the pandemic. Providers are thinking outside the box to combat the opioid crisis
Ways Decentralized Clinical Trials Can Expand Diversity & Improve Participation Rates